...
首页> 外文期刊>Lymphatic research and biology >Bioelectrical Impedance for Detecting and Monitoring Lymphedema in Patients with Breast Cancer. Preliminary Results of the Florence Nightingale Breast Study Group
【24h】

Bioelectrical Impedance for Detecting and Monitoring Lymphedema in Patients with Breast Cancer. Preliminary Results of the Florence Nightingale Breast Study Group

机译:用于检测和监测乳腺癌患者淋巴水肿的生物电阻抗。弗洛伦斯·南丁格尔乳房研究小组的初步结果

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to evaluate the efficacy of bioimpedance spectroscopy for the follow-up of patients with lymphedema in Turkey and its benefits in the diagnosis of stage 0, 1, and 2 lymphedema in patients who are under treatment for breast cancer. Thirty-seven female patients with breast cancer who underwent surgical procedures in our Breast Health Centre were followed up for lymphedema using bioimpedance, and clinical measurements were taken for a minimum period of 1 year at 3-month intervals. Patients who had been monitored regularly between November, 2011, and September, 2013, were enrolled to the study. In total, 8 patients developed lymphedema with an overall rate of 21.6%. Among the 8 patients who developed lymphedema, 4 had Stage 2, 1 had Stage 1, and 3 had Stage 0 lymphedema. Stage 0 lymphedema could not be detected with clinical measurements. During the patients' 1-year follow-up period using measurements of bioimpedance, a statistically significant relationship was observed between the occurrence of lymphedema and the disease characteristics. including the number of the extracted and remaining lymph nodes and the region of radiotherapy (p=0.042, p=0.024, p=0.040). Bioimpedance analysis seems to be a practical and reliable method for the early diagnosis of lymphedema. It is believed that regular monitoring of patients in the high-risk group using bioimpedance analyses increases the ability to treat lymphedema.
机译:这项研究的目的是评估生物阻抗谱在土耳其淋巴水肿患者中的随访效果,以及对乳腺癌治疗患者的0、1、2期淋巴水肿的诊断价值。在我们的乳腺癌健康中心接受外科手术的37例女性乳腺癌患者接受了生物阻抗的淋巴水肿随访,并至少每3个月进行1年的临床测量。在2011年11月至2013年9月期间接受定期监测的患者入选了该研究。共有8例患者出现淋巴水肿,总发生率为21.6%。在发生淋巴水肿的8例患者中,有4例为2期,1例为1期,3例为0期淋巴水肿。临床测量无法检测到0期淋巴水肿。在使用生物阻抗测量的患者的1年随访期间,观察到淋巴水肿的发生与疾病特征之间的统计学显着关系。包括提取的和剩余的淋巴结数目以及放疗区域(p = 0.042,p = 0.024,p = 0.040)。生物阻抗分析似乎是淋巴水肿早期诊断的一种实用且可靠的方法。据信,使用生物阻抗分析对高危人群进行定期监测可提高治疗淋巴水肿的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号